Passionate about making a profound impact on patients’ lives

Assembly Bio is an ambitious biopharmaceutical company with cutting-edge therapeutic clinical candidates capable of improving the lives of millions living with chronic hepatitis B virus (HBV) infection around the world, and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including HBV, hepatitis delta virus (HDV) and herpesviruses.

Focused on Transforming Treatment of Serious Viral Diseases

Assembly Bio’s team aspires to advance treatment options for patients through the discovery and development of novel antivirals. We aim to deliver finite and curative therapies for HBV, one of the world’s most prevalent and devastating infectious diseases, and to progress differentiated research programs directed at serious viral diseases.

Explore our programs.


Board of Directors

William Ringo

Chairman of the Board, Non-Executive

Anthony Altig

Director

Gina Consylman

Director

Richard DiMarchi, PhD

Director

Sir Michael Houghton, PhD

Director

Lisa Johnson-Pratt, MD

Director

Sue Mahony, PhD

Director

John McHutchison AO, MD

Director

Jason Okazaki

President & Chief Executive Officer, Director

Scientific Advisory Board

Antonio Bertoletti, MD

Richard DiMarchi, PhD

Edward J. Gane, MBCHB, MD, FRACP, MNZM

Sir Michael Houghton, PhD

Patrick Kennedy, MB BCh BAO BMedSci FR CP MD

Alex Thompson, MBBS, PhD, FRACP

Stephan Urban, PhD

Adam Zlotnick, PhD

Fabien Zoulim, MD, PhD
 

Contact Us

CORPORATE HEADQUARTERS
331 Oyster Point Blvd.
4th Floor
South San Francisco, CA 94080

Get Directions

FOR GENERAL INFORMATION,
PLEASE CONTACT:

833.509.4583
info@assemblybio.com

FOR QUESTIONS ABOUT COLLABORATION
OPPORTUNITIES, PLEASE CONTACT:

BD@assemblybio.com